Case report: Resolution of VIPoma-related symptoms with peptide receptor radionuclide therapy
Peptide receptor radionuclide therapy (PRRT) is used for the management of neuroendocrine tumors (NETs) not responsive to somatostatin analogs. In this case series, we report two patients with pancreatic vasoactive intestinal peptide (VIP)-secreting NETs (VIPomas) not responsive to any other therapi...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1432758/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841555127555588096 |
|---|---|
| author | Turgut Bora Cengiz Raksha Kulkarni Virginia Corbett Nasrin V. Ghesani Edward Wolin Munir V. Ghesani |
| author_facet | Turgut Bora Cengiz Raksha Kulkarni Virginia Corbett Nasrin V. Ghesani Edward Wolin Munir V. Ghesani |
| author_sort | Turgut Bora Cengiz |
| collection | DOAJ |
| description | Peptide receptor radionuclide therapy (PRRT) is used for the management of neuroendocrine tumors (NETs) not responsive to somatostatin analogs. In this case series, we report two patients with pancreatic vasoactive intestinal peptide (VIP)-secreting NETs (VIPomas) not responsive to any other therapies who achieved symptomatic control and a significant decrease in serum VIP levels with PRRT during their hospital stay. Two patients with VIPomas were admitted to the hospital with multiple prior hospital admissions after going through multiple lines of therapy. The first patient was a 47-year-old woman with a grade 2 pancreatic VIP-secreting NET. She was treated with somatostatin analogs and chemotherapy; however, she experienced recurrent symptoms and complications leading to two hospital admissions, one of which included an intensive care unit (ICU) admission. The patient was treated with lutetium-177 DOTATATE while in the hospital, which led to the resolution of the symptoms and a marked decline in serum VIP levels, and she was able to be discharged from the hospital after 147 days of hospitalization (16 days after PRRT). The second patient was a 27-year-old man who was diagnosed with a well-differentiated grade 3 pancreatic VIPoma. He also suffered from severe diarrhea and was not responsive to any form of therapy, including liver embolization. He was also treated with PRRT on admission, which led to immediate resolution of his symptoms and a decrease in tumor markers. In conclusion, 177Lu-DOTATATE is an effective treatment for highly symptomatic VIPoma. Inpatient administration of PRRT can rapidly reduce diarrhea and fluid and electrolyte complications of VIP secretion and may shorten hospital stays. |
| format | Article |
| id | doaj-art-f0ba9dafdcb24cdd99ff58f4cc0596ad |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-f0ba9dafdcb24cdd99ff58f4cc0596ad2025-01-08T06:12:08ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-01-011410.3389/fonc.2024.14327581432758Case report: Resolution of VIPoma-related symptoms with peptide receptor radionuclide therapyTurgut Bora Cengiz0Raksha Kulkarni1Virginia Corbett2Nasrin V. Ghesani3Edward Wolin4Munir V. Ghesani5Department of Nuclear Medicine, Mount Sinai Hospital at Icahn School of Medicine, New York, NY, United StatesDepartment of Nuclear Medicine, Mount Sinai Hospital at Icahn School of Medicine, New York, NY, United StatesDepartment of Hematology and Oncology, Mount Sinai Hospital at Icahn School of Medicine, New York, NY, United StatesDepartment of Nuclear Medicine, Mount Sinai Hospital at Icahn School of Medicine, New York, NY, United StatesDepartment of Hematology and Oncology, Mount Sinai Hospital at Icahn School of Medicine, New York, NY, United StatesDepartment of Nuclear Medicine, Mount Sinai Hospital at Icahn School of Medicine, New York, NY, United StatesPeptide receptor radionuclide therapy (PRRT) is used for the management of neuroendocrine tumors (NETs) not responsive to somatostatin analogs. In this case series, we report two patients with pancreatic vasoactive intestinal peptide (VIP)-secreting NETs (VIPomas) not responsive to any other therapies who achieved symptomatic control and a significant decrease in serum VIP levels with PRRT during their hospital stay. Two patients with VIPomas were admitted to the hospital with multiple prior hospital admissions after going through multiple lines of therapy. The first patient was a 47-year-old woman with a grade 2 pancreatic VIP-secreting NET. She was treated with somatostatin analogs and chemotherapy; however, she experienced recurrent symptoms and complications leading to two hospital admissions, one of which included an intensive care unit (ICU) admission. The patient was treated with lutetium-177 DOTATATE while in the hospital, which led to the resolution of the symptoms and a marked decline in serum VIP levels, and she was able to be discharged from the hospital after 147 days of hospitalization (16 days after PRRT). The second patient was a 27-year-old man who was diagnosed with a well-differentiated grade 3 pancreatic VIPoma. He also suffered from severe diarrhea and was not responsive to any form of therapy, including liver embolization. He was also treated with PRRT on admission, which led to immediate resolution of his symptoms and a decrease in tumor markers. In conclusion, 177Lu-DOTATATE is an effective treatment for highly symptomatic VIPoma. Inpatient administration of PRRT can rapidly reduce diarrhea and fluid and electrolyte complications of VIP secretion and may shorten hospital stays.https://www.frontiersin.org/articles/10.3389/fonc.2024.1432758/fullPRRTVIPomainpatient PRRTneuroendocrine tumorpancreatic net68Ga DOTATATE PET/CT |
| spellingShingle | Turgut Bora Cengiz Raksha Kulkarni Virginia Corbett Nasrin V. Ghesani Edward Wolin Munir V. Ghesani Case report: Resolution of VIPoma-related symptoms with peptide receptor radionuclide therapy Frontiers in Oncology PRRT VIPoma inpatient PRRT neuroendocrine tumor pancreatic net 68Ga DOTATATE PET/CT |
| title | Case report: Resolution of VIPoma-related symptoms with peptide receptor radionuclide therapy |
| title_full | Case report: Resolution of VIPoma-related symptoms with peptide receptor radionuclide therapy |
| title_fullStr | Case report: Resolution of VIPoma-related symptoms with peptide receptor radionuclide therapy |
| title_full_unstemmed | Case report: Resolution of VIPoma-related symptoms with peptide receptor radionuclide therapy |
| title_short | Case report: Resolution of VIPoma-related symptoms with peptide receptor radionuclide therapy |
| title_sort | case report resolution of vipoma related symptoms with peptide receptor radionuclide therapy |
| topic | PRRT VIPoma inpatient PRRT neuroendocrine tumor pancreatic net 68Ga DOTATATE PET/CT |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2024.1432758/full |
| work_keys_str_mv | AT turgutboracengiz casereportresolutionofvipomarelatedsymptomswithpeptidereceptorradionuclidetherapy AT rakshakulkarni casereportresolutionofvipomarelatedsymptomswithpeptidereceptorradionuclidetherapy AT virginiacorbett casereportresolutionofvipomarelatedsymptomswithpeptidereceptorradionuclidetherapy AT nasrinvghesani casereportresolutionofvipomarelatedsymptomswithpeptidereceptorradionuclidetherapy AT edwardwolin casereportresolutionofvipomarelatedsymptomswithpeptidereceptorradionuclidetherapy AT munirvghesani casereportresolutionofvipomarelatedsymptomswithpeptidereceptorradionuclidetherapy |